Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03357081 · ClinicalTrials.gov registry record
Utility of Real-Time Contrast Enhanced Ultrasound (CEUS) in the Evaluation of Soft Tissue Hematomas
A clinical trial of Hematoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT03357081: Completed study of Hematoma, sponsored by Mayo Clinic.
NCT03357081 is a study of Hematoma that has completed, run by Mayo Clinic. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03357081, a study of Hematoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Traumatic and non-traumatic soft tissue hematomas are frequently encountered in the acute care setting. The incidence of these hematomas appears to be on the rise secondary to the increased use of anticoagulants among older patients for a variety of medical conditions. The management of soft tissue hematomas depends on the accurate diagnosis of any ongoing bleeding as well as of identification of the injured vessel type. While the majority of cases can be managed conservatively, expanding hematomas leading to hemodynamic instability or ongoing blood loss might require embolization or surgical intervention. The mainstay diagnostic imaging modality is multidetector computed tomography (MDCT) with intravenous contrast that allows accurate assessment of hematoma size, location as well as evaluation for active extravasation. However, many patients cannot undergo CT imaging due to underlying kidney disease, allergy to contrast, or due to concerns for radiation exposure, especially in young age. Currently there are no alternative tests for these patients with a similarly high diagnostic accuracy available. This study intends to establish an imaging protocol and investigate the utility of contrast-enhanced ultrasound (CEUS) in the diagnostic work-up of soft tissue hematoma as an ionizing radiation-free alternative to computed tomography (CT) that can be used independent from the kidney function of the patient.
Primary Outcome
Contrast outside of the blood vessel indicates ongoing bleeding
Conditions Studied
Interventions
- DRUG CEUS or Contrast enhanced Ultrasound
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2019-09-22 |
What the finished NCT03357081 record still lists
NCT03357081 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 1 condition, with Hematoma appearing as the primary indexed condition, and to 1 intervention - of which CEUS or Contrast enhanced Ultrasound is the first listed.
NCT03357081 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03357081 about?
NCT03357081 is a clinical study titled "Utility of Real-Time Contrast Enhanced Ultrasound (CEUS) in the Evaluation of Soft Tissue Hematomas". Traumatic and non-traumatic soft tissue hematomas are frequently encountered in the acute care setting. The incidence of these hematomas appears to be on the rise secondary to the increased use of anticoagulants among older patients for a variety of medical conditions. The management of soft tissue...
What is the current status of trial NCT03357081?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2018-02-27. Estimated completion is 2019-09-22.
What conditions does trial NCT03357081 study?
This clinical trial studies the following conditions: Hematoma.
What interventions are being tested in trial NCT03357081?
The interventions under investigation include: CEUS or Contrast enhanced Ultrasound (DRUG).
Who is sponsoring clinical trial NCT03357081?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03357081 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI